1) Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency (XSCID) in Older Children, Young Adults with Impaired Immunity 2) A New Approach to Cancer Immunotherapy Targeting Unique Cancer Mutations

Lentivector Gene Therapy for X-linked Severe Combined Immune Deficiency (XSCID) in Older Children, Young Adults with Impaired Immunity and Recurrent Infections Despite Prior Haplo-transplant Harry L. Malech, MD Chief, Laboratory of Host Defenses and Chief, Genetic Immunotherapy Section, NIAID A New Approach to Cancer Immunotherapy Targeting Unique Cancer Mutations Steven A. Rosenberg, MD, PhD Chief, Surgery Branch, NCI For more information go to http://www.cc.nih.gov/about/news/grcurrent.htmlAir date: 9/30/2015 12:00:00 PM
Source: Videocast - All Events - Category: Journals (General) Tags: Upcoming Events Source Type: video